Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166480 | 0.84 | HDAC6 (0.46) | HDAC6HDAC8GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18170344 | 0.84 | HDAC6 (0.46) | HDAC6HDAC8GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18184323 | 0.84 | HDAC6 (0.46) | HDAC6HDAC8GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18170343 | 0.84 | HDAC6 (0.46) | HDAC6HDAC8GRIN2DGRIN3BGRIN1 | |
| SCHEMBL16884223 | 0.71 | SCN9A (0.44) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL16884198 | 0.68 | CNR2 (0.44) | HDAC6EPHX2 | |
| SCHEMBL31137114 | 0.68 | KDM1A (0.47) | HDAC6 | |
| SCHEMBL16884338 | 0.68 | SCN9A (0.46) | HDAC6HDAC8HDAC1HDAC3 | |
| SCHEMBL22927151 | 0.68 | CYP2D6 (0.41) | HDAC6HDAC8GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13641428 | 0.66 | HDAC6 (0.45) | HDAC6HDAC8HDAC1HDAC3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039727-B2 | Adamantane or pinene derivatives for use in the treatment of chlamydiales infections | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-08-07 | — | — | US | disclosed |
| US-20160310448-A1 | Adamantane or Pinene Derivatives for Use in the Treatment of Chlamydiales Infections | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039727-B2 | Adamantane or pinene derivatives for use in the treatment of chlamydiales infections | ADRA1A, ADRA1B, ADRA1D | HDAC6 4361/4885HDAC8 4222/4885GRIN2D 3507/4885 |
| US-20160310448-A1 | Adamantane or Pinene Derivatives for Use in the Treatment of Chlamydiales Infections | ADRA1A, ADRA1B, ADRA1D | HDAC6 4267/4885HDAC8 4223/4885GRIN2D 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.